Skip to main content
. 2014 Jul 28;25(11):2267–2271. doi: 10.1093/annonc/mdu362

Figure 3.

Figure 3.

Recurrent genomic aberrations identified by comparative genomic hybridization in synovial sarcoma patients treated with neoadjuvant chemotherapy. (A) Patients with good and intermediate overall response to chemotherapy. (B) Patients with poor overall response to chemotherapy. Arrows indicate aberrations present in more than 20% of cases.